FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2156-2158 November 18, 2004 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fischer, M. A. PubMed Citation

Spending for prescription drugs represents more than 10 percent of the nation's health care costs and is currently the fastest-growing component of health care expenditures.¹ The rapid increase in drug spending has resulted from the expansion of the volume of medications prescribed, as well as a shift toward the inclusion of more new and expensive drugs. Medicaid programs have been especially vulnerable to the skyrocketing spending on drugs, which has often exacerbated state budget woes. Increasing at more than twice the rate of overall Medicaid spending, Medicaid expenditures for prescription drugs rose 18 percent annually between 1997 and 2000.²

Medicaid . . . [Full Text of this Article]

This article has been cited by other articles:

• Jackevicius, C. A., Tu, J. V., Demers, V., Melo, M., Cox, J., Rinfret, S., Kalavrouziotis, D., Johansen, H., Behlouli, H., Newman, A., Pilote, L. (2008). Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel. NEJM 359: 1802-1810 [Abstract] [Full Text]  
• Polinski, J. M., Wang, P. S., Fischer, M. A. (2007). Medicaid's Prior Authorization Program And Access To Atypical Antipsychotic Medications. Health Aff (Millwood) 26: 750-760 [Abstract] [Full Text]